The abundance of CAFs positive for LRRC15+ (leucine-rich repeat-containing 15) is correlated with poor outcomes following immunotherapy across six cancer types, such as renal cell carcinoma, head and neck cancer, and NSCLC [12]. This evidence concerns the gene LRRC15 and cancer.